Kodiak Sciences Inc
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
About
CEO
Dr. Victor Perlroth M.D.
Employees
111
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
1200 Page Mill Road, Palo Alto, CA 94304, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 13, 2025 | — | — | — | — |
| Aug 12, 2025 | — | — | — | — |
| May 13, 2025 | — | — | — | — |
| Mar 26, 2025 | — | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 0 | — | 5 |
| Average estimate | — | 0.00 | — | -3.73 |
| Low estimate | — | 0.00 | — | -4.37 |
| High estimate | — | 0.00 | — | -2.98 |
| Last year EPS | — | — | — | -3.39 |
[stock_revenue_estimate]
Growth estimates
Current qtr
24.030%
Next qtr. (Mar 2025)
—
Current year
31.840%
Next year (Dec 2025)
-9.970%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 206.30M | 267.59M | 217.34M | 107.39M | 37.51M |
| Selling general and admin | 71.02M | 73.79M | 49.71M | 28.62M | 11.68M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -277.32M | -341.38M | -267.05M | -136.01M | -49.19M |
| Non operating interest income | |||||
| Income | 16.73M | 7.07M | 298,000 | 2.97M | 1.57M |
| Expense | 13,000 | 18,000 | 47,000 | 25,000 | 8,000 |
| Other income expense | 110,000 | 503,000 | -190,000 | -30,000 | 265,000 |
| Pretax income | -260.49M | -333.82M | -266.99M | -133.10M | -47.37M |
| Tax provision | — | — | — | — | — |
| Net income | -260.49M | -333.82M | -266.99M | -133.10M | -47.37M |
| Basic EPS | -4.97 | -6.39 | -5.16 | -2.91 | -1.25 |
| Diluted EPS | -4.97 | -6.39 | -5.16 | -2.91 | -1.25 |
| Basic average shares | 52.41M | 52.25M | 51.79M | 45.74M | 37.85M |
| Diluted average shares | 52.41M | 52.25M | 51.79M | 45.74M | 37.85M |
| EBITDA | -234.53M | -322.80M | -258.23M | -128.86M | -46.45M |
| Net income from continuing op. | -260.49M | -333.82M | -266.99M | -133.10M | -47.37M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 479.37M | 666.63M | 904.22M | 1.07B | 358.87M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 285.51M | 190.43M | 731.51M | 944.40M | 211.80M |
| Other short term investments | — | 288.50M | — | 24.58M | 124.68M |
| Accounts receivable | — | — | — | — | — |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | 3.30M | 3.03M | 2.75M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 3.80M | 7.07M | 3.30M | 3.03M | 2.75M |
| Non current assets | |||||
| Properties | 54.54M | 59.37M | 66.74M | 77.02M | 2.92M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 42.13M | 15.11M | 5.18M | 441,000 | 377,000 |
| Construction in progress | 4.37M | 4.52M | 37.81M | 2.23M | — |
| Leases | 96.53M | 43.48M | 1.29M | 1.29M | 1.27M |
| Accumulated depreciation | -22.55M | -6.72M | -2.94M | -2.17M | -1.77M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | 11.70M |
| Other non current assets | 15.04M | 64.87M | 61.34M | 16.53M | 5.15M |
| Total liabilities | 213.59M | 230.46M | 240.90M | 206.60M | 13.51M |
| Current liabilities | |||||
| Accounts payable | 13.61M | 9.13M | 12.43M | 8.65M | 2.62M |
| Accrued expenses | 18.35M | 33.44M | 48.32M | 20.40M | 8.66M |
| Short term debt | 9.77M | 9.93M | 3.93M | 2.37M | 434,000 |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | — | -1,000 | — | — | — |
| Non current liabilities | |||||
| Long term debt | 71.86M | 77.81M | 76.06M | 75.03M | 1.50M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 100.00M | 100.16M | 211,000 | 256,000 | 295,000 |
| Shareholders equity | |||||
| Common stock | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 |
| Retained earnings | -1.15B | -892.04M | -558.22M | -291.23M | -158.13M |
| Other shareholders equity | — | -1.31M | — | 53,000 | 10,000 |
| Total shareholders equity | 265.78M | 436.17M | 663.32M | 860.75M | 345.36M |
| Additional paid in capital | 1.42B | 1.33B | 1.22B | 1.15B | 503.48M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | -260.49M | -333.82M | -266.99M | -133.10M | -47.37M | -41.44M | -27.94M | -17.13M |
| Depreciation | 25.95M | 11.00M | 8.71M | 4.21M | 911,000 | 490,000 | 549,000 | 257,000 |
| Deferred Taxes | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 88.56M | 106.03M | 61.39M | 30.67M | 6.11M | 2.67M | 275,000 | 272,000 |
| Other Non-Cash Items | 4,000 | -563,000 | 53,000 | 49,000 | — | 5.48M | 1.16M | — |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Accounts Payable | 5.60M | 1.66M | -2.09M | 5.22M | 1.57M | -2.32M | 2.28M | 23,000 |
| Other Assets & Liabilities | -8.50M | 15.29M | 3.28M | -3.77M | -9.41M | 31,000 | 56,000 | 21,000 |
| Operating Cash Flow | -148.88M | -200.40M | -195.66M | -96.72M | -48.18M | -35.10M | -23.61M | -16.56M |
| Investing Activities | ||||||||
| Capital Expenditures | -41.43M | -47.36M | -63.30M | -7.00M | -437,000 | -581,000 | -209,000 | -771,000 |
| Net Intangibles | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — |
| Purchase of Investments | -49.35M | -427.77M | — | -86.32M | -150.96M | — | — | — |
| Sale of Investments | 340.00M | 138.62M | 24.50M | 198.15M | 14.40M | — | — | — |
| Investing Cash Flow | 249.23M | -336.51M | -38.80M | 104.83M | -137.00M | -581,000 | -209,000 | -771,000 |
| Financing Activities | ||||||||
| Long-Term Debt Issuance | — | — | — | — | — | 33.00M | 10.00M | — |
| Long-Term Debt Payments | — | — | — | -5,000 | -48,000 | -108,000 | -97,000 | -62,000 |
| Other Financing Charges | -211,000 | -49,000 | -45,000 | 99.61M | -36,000 | -225,000 | -269,000 | -59,000 |
| Financing Cash Flow | -211,000 | -49,000 | -45,000 | 711.13M | 297.40M | 116.42M | 9.63M | -121,000 |
| Other Cash Details | ||||||||
| End Cash Position | 291.83M | 196.76M | 737.83M | 950.72M | 211.94M | 88.39M | 1.54M | 9.76M |
| Income Tax Paid | — | — | — | — | — | — | — | — |
| Interest Paid | 13,000 | 18,000 | 22,000 | 25,000 | 8,000 | 19,000 | 24,000 | 6,000 |
| Free Cash Flow | -195.61M | -253.82M | -245.57M | -90.43M | -39.58M | -29.61M | -17.86M | -16.82M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 982,015 | 5.74M | 1.87% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 870,607 | 5.09M | 1.65% |
| BlackRock Advantage Small Cap Core Fund | Nov 30, 2024 | 539,215 | 3.15M | 1.02% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 458,129 | 2.68M | 0.87% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 332,968 | 1.95M | 0.63% |
| iShares Russell 2000 Value ETF | Nov 30, 2024 | 333,031 | 1.95M | 0.63% |
| Bruce & Co., Inc. | Dec 31, 2024 | 323,000 | 1.89M | 0.61% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 181,585 | 1.06M | 0.35% |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | Nov 30, 2024 | 165,396 | 967,566 | 0.31% |
| Vanguard Russell 2000 Index Fund | Nov 30, 2024 | 151,342 | 885,350 | 0.29% |
Article
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
PALO ALTO, Calif. , Feb. 4, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA.
Feb 4, 2025
Article
Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
PALO ALTO, Calif. , Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D.
Jan 7, 2025
Article
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.
Jan 6, 2025
